Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study
dc.rights.license | open | en_US |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | GOUVERNEUR, Amandine | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | COUTUREAU, J. | |
dc.contributor.author | JOVE, J. | |
dc.contributor.author | ROUYER, M. | |
dc.contributor.author | GRELAUD, A. | |
dc.contributor.author | DUC, S. | |
dc.contributor.author | GERARD, S. | |
dc.contributor.author | SMITH, D. | |
dc.contributor.author | RAVAUD, A. | |
dc.contributor.author | DROZ, C. | |
dc.contributor.author | BERNARD, M. A. | |
dc.contributor.author | LASSALLE, R. | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | FORRIER-REGLAT, Annie | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | NOIZE, Pernelle | |
dc.date.accessioned | 2020-06-22T15:04:41Z | |
dc.date.available | 2020-06-22T15:04:41Z | |
dc.date.issued | 2019-03 | |
dc.identifier.issn | 1938-0674 (Electronic) 1533-0028 (Linking) | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/8069 | |
dc.description.abstractEn | BACKGROUND: Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Their real-life evaluation is insufficient, especially in elderly and frail patients. The aim was to describe use, safety, and effectiveness of targeted therapies in first-line mCRC treatment according to age. PATIENTS AND METHODS: Two field cohorts of patients initiating bevacizumab or cetuximab for first-line mCRC were pooled. Patients characteristics, use, and safety were compared between younger and elderly patients (<75 vs. >/=75 years). Two-year overall survival (OS) and progression-free survival (PFS) were estimated in both age groups using the Kaplan-Meier method adjusted on factors associated with death or progression identified with Cox multivariate modeling. RESULTS: Eight hundred patients (n = 411, 51.4% bevacizumab) were included: 498 (62.3%) male, median age 64 years, 118 (14.8%) Eastern Cooperative Oncology Group performance status (ECOG-PS) >/=2. Elderly patients (n = 126, 15.8%) were more often treated with 5-fluorouracil alone than younger. Severe adverse events were equivalent across age groups. ECOG-PS >/=1, abnormal hemoglobin, and abnormal alkaline phosphatases were associated with a higher risk of death; OS adjusted on these factors was similar between elderly and younger patients. ECOG-PS >/=1, lung metastases, abnormal hemoglobin, and abnormal creatinine clearance were associated with a higher risk of progression or death; PFS adjusted on these factors was similar across groups. CONCLUSION: Despite treatment adaptations, elderly patients could benefit from targeted therapies as younger without safety warning. | |
dc.language.iso | EN | en_US |
dc.subject.en | PharmacoEpi-Drugs | |
dc.subject.en | CIC1401 | |
dc.title.en | Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study | |
dc.title.alternative | Clin Colorectal Cancer | en_US |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1016/j.clcc.2018.11.005 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 30630730 | en_US |
bordeaux.journal | Clinical Colorectal Cancer | en_US |
bordeaux.page | e150-e162 | en_US |
bordeaux.volume | 18 | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.issue | 1 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.identifier | hal-03210810 | |
hal.version | 1 | |
hal.date.transferred | 2021-04-29T01:49:43Z | |
hal.export | true | |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Colorectal%20Cancer&rft.date=2019-03&rft.volume=18&rft.issue=1&rft.spage=e150-e162&rft.epage=e150-e162&rft.eissn=1938-0674%20(Electronic)%201533-0028%20(Linking)&rft.issn=1938-0674%20(Electronic)%201533-0028%20(Linking)&rft.au=GOUVERNEUR,%20Amandine&COUTUREAU,%20J.&JOVE,%20J.&ROUYER,%20M.&GRELAUD,%20A.&rft.genre=article |
Fichier(s) constituant ce document
Fichiers | Taille | Format | Vue |
---|---|---|---|
Il n'y a pas de fichiers associés à ce document. |